Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Pharmacogenetics of warfarin: challenges and opportunities.

Lee MT, Klein TE.

J Hum Genet. 2013 Jun;58(6):334-8. doi: 10.1038/jhg.2013.40. Epub 2013 May 9. Review.

2.

Warfarin Pharmacogenetics: New Life for an Old Drug.

Wen MS, Lee MT.

Acta Cardiol Sin. 2013 May;29(3):235-42. Review.

3.

Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation.

Cho HJ, On YK, Bang OY, Kim JW, Huh W, Ko JW, Kim JS, Lee SY.

Clin Ther. 2011 Oct;33(10):1371-80. doi: 10.1016/j.clinthera.2011.09.004. Epub 2011 Oct 6.

PMID:
21981797
4.

A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation.

Wei M, Ye F, Xie D, Zhu Y, Zhu J, Tao Y, Yu F.

Thromb Haemost. 2012 Jun;107(6):1083-91. doi: 10.1160/TH11-12-0848. Epub 2012 Apr 26.

PMID:
22534826
5.

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.

Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, Stein CM, Anderson JL, Kimmel SE, Lee MT, Pirmohamed M, Wadelius M, Klein TE, Altman RB; Clinical Pharmacogenetics Implementation Consortium.

Clin Pharmacol Ther. 2011 Oct;90(4):625-9. doi: 10.1038/clpt.2011.185. Epub 2011 Sep 7. Review.

6.

Warfarin pharmacogenetics: does more accurate dosing benefit patients?

Eby C.

Semin Thromb Hemost. 2012 Oct;38(7):661-6. doi: 10.1055/s-0032-1326789. Epub 2012 Oct 9. Review.

7.

Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice.

Becquemont L.

Eur J Clin Pharmacol. 2008 Oct;64(10):953-60. doi: 10.1007/s00228-008-0542-2. Epub 2008 Aug 30. Review.

PMID:
18758764
8.

The pharmacogenetics of the response to warfarin in Chinese.

Lam MP, Cheung BM.

Br J Clin Pharmacol. 2012 Mar;73(3):340-7. doi: 10.1111/j.1365-2125.2011.04097.x. Review.

9.

Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy.

Gong IY, Tirona RG, Schwarz UI, Crown N, Dresser GK, Larue S, Langlois N, Lazo-Langner A, Zou G, Roden DM, Stein CM, Rodger M, Carrier M, Forgie M, Wells PS, Kim RB.

Blood. 2011 Sep 15;118(11):3163-71. doi: 10.1182/blood-2011-03-345173. Epub 2011 Jul 1.

10.

Warfarin pharmacogenetics.

Limdi NA, Veenstra DL.

Pharmacotherapy. 2008 Sep;28(9):1084-97. doi: 10.1592/phco.28.9.1084. Review.

11.

Warfarin pharmacogenetics: to genotype or not to genotype, that is the question.

Cavallari LH, Nutescu EA.

Clin Pharmacol Ther. 2014 Jul;96(1):22-4. doi: 10.1038/clpt.2014.78. Review.

PMID:
24942399
12.

Evaluation of genetic factors for warfarin dose prediction.

Caldwell MD, Berg RL, Zhang KQ, Glurich I, Schmelzer JR, Yale SH, Vidaillet HJ, Burmester JK.

Clin Med Res. 2007 Mar;5(1):8-16. Erratum in: Clin Med Res. 2007 Jun;5(2):142.

13.

[Application of warfarin pharmacogenetics].

Tomek A, Mat'oska V, Kumstýrfová T, Táborský L.

Vnitr Lek. 2009 Jun;55(6):565-9. Review. Czech.

PMID:
19662888
14.

Proposal of pharmacogenetics-based warfarin dosing algorithm in Korean patients.

Choi JR, Kim JO, Kang DR, Yoon SA, Shin JY, Zhang X, Roh MO, Hong HJ, Wang YP, Jo KH, Lee KS, Yun HJ, Oh YS, Yoo KD, Jeon HG, Lee YS, Kang TS, Park HJ, Chung MW, Kang JH.

J Hum Genet. 2011 Apr;56(4):290-5. doi: 10.1038/jhg.2011.4. Epub 2011 Feb 17.

PMID:
21326313
15.

Understanding the pharmacogenetic approach to warfarin dosing.

Glurich I, Burmester JK, Caldwell MD.

Heart Fail Rev. 2010 May;15(3):239-48. doi: 10.1007/s10741-008-9115-9. Epub 2008 Nov 8. Review.

PMID:
18998206
16.

Warfarin pharmacogenetics: development of a dosing algorithm for Omani patients.

Pathare A, Al Khabori M, Alkindi S, Al Zadjali S, Misquith R, Khan H, Lapoumeroulie C, Paldi A, Krishnamoorthy R.

J Hum Genet. 2012 Oct;57(10):665-9. doi: 10.1038/jhg.2012.94. Epub 2012 Aug 2.

PMID:
22854539
17.

Pharmacogenetics of vitamin K antagonists: useful or hype?

Lippi G, Franchini M, Favaloro EJ.

Clin Chem Lab Med. 2009;47(5):503-15. doi: 10.1515/CCLM.2009.140. Review.

PMID:
19397481
18.

[Possible application of pharmacogenomics to warfarin therapy].

Murata M.

Rinsho Byori. 2011 Jun;59(6):594-7. Review. Japanese.

PMID:
21815482
19.

Failure of pharmacogenetic-based dosing algorithms to identify older patients requiring low daily doses of warfarin.

Schwartz JB, Kane L, Moore K, Wu AH.

J Am Med Dir Assoc. 2011 Nov;12(9):633-8. doi: 10.1016/j.jamda.2010.12.006. Epub 2011 Jan 26.

PMID:
21450231
20.

Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.

Kimura R, Miyashita K, Kokubo Y, Akaiwa Y, Otsubo R, Nagatsuka K, Otsuki T, Okayama A, Minematsu K, Naritomi H, Honda S, Tomoike H, Miyata T.

Thromb Res. 2007;120(2):181-6. Epub 2006 Oct 17.

PMID:
17049586

Supplemental Content

Support Center